Join our daily newsletter At The Bell to receive exclusive market insights
- Pharmaxis (PXS) releases the final set of interim data from its phase two cancer trial, revealing “excellent” results
- Ten patients with bone marrow cancer, myelofibrosis, completed six months of treatment with PXS-5505
- Sixty per cent of patients showed “significant” improvement in the fibrosis grade in bone marrow biopsies
- The treatment has been well tolerated, with no serious adverse events reported, and has promising signs of clinical efficacy
- Shares are up 3.85 per cent, trading at 5.4 cents at 1:52 pm AEST
Pharmaxis (PXS) has released the final set of interim data from its phase two cancer trial, revealing “excellent” results.
Ten patients with bone marrow cancer, myelofibrosis, completed six months of treatment with PXS-5505, with 60 per cent of patients showing “significant” improvement in the fibrosis grade in bone marrow biopsies.
The phase two trial is designed to demonstrate PXS-5505, an inhibitor of all lysyl oxidase enzymes (LOX), as a safe and effective treatment in myelofibrosis patients who are intolerant, unresponsive, or ineligible for treatment with other approved drugs.
Patients under these conditions have limited treatment options with a life expectancy of around one year.
The treatment has been well tolerated, with no serious adverse events reported, and has promising signs of clinical efficacy.
The drug benefits include improved symptom scores, stable or improved hematological parameters, and reduced bone marrow fibrosis.
The original trial had 21 patients involved; however, 10 patients dropped out of the study due to a lack of clinical response or adverse events unrelated to the drug.
Later this year, final results from the trial will be submitted for presentation at the American Society of Haematology conference.
PXS shares were up 3.85 per cent, trading at 5.4 cents at 1:52 pm AEST.
